Targets in ALS: designing multidrug therapies

Maria Teresa Carrì, Giuliano Grignaschi, Caterina Bendotti

Research output: Contribution to journalArticlepeer-review


Amyotrophic lateral sclerosis (ALS) is an incurable disease that arises from the progressive loss of motoneurons. Even when caused by a single gene defect, as in the case of mutations in the enzyme Cu-Zn superoxide dismutase (SOD1), ALS is the result of a complex cascade that involves crosstalk among motoneurons, glia and muscles, and evolves through the action of converging toxic mechanisms. Transgenic rodents that express human mutant SOD1 and develop a progressive paralytic disease are widely used to screen potential therapeutics. Treatments that interfere with a specific event in the neurotoxic cascade have been reported to produce a modest increase in rodent lifespan. Multi-intervention approaches, including novel methods to intercept the damage and to deliver molecules to vulnerable cells, have recently been shown to be more effective. Thus, new avenues for promising therapeutic approaches can be derived from multidrug treatments and/or the delivery of growth factors by viral vectors, in combination with exercise and/or diet regimens.

Original languageEnglish
Pages (from-to)267-273
Number of pages7
JournalTrends in Pharmacological Sciences
Issue number5
Publication statusPublished - May 2006

ASJC Scopus subject areas

  • Pharmacology
  • Toxicology


Dive into the research topics of 'Targets in ALS: designing multidrug therapies'. Together they form a unique fingerprint.

Cite this